Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 632-619-2 | CAS number: 881685-58-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Specific investigations: other studies
Administrative data
- Endpoint:
- specific investigations: other studies
- Remarks:
- Liver enzyme induction in rat hepatocytes
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 14 Jun 2010 to 16 July 2010
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 011
- Report date:
- 2011
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- This study was intended to investigate the ability of the test material to induce cytochrome P450 (CYP) 2B (CYP2B) activity, CYP3A activity and cell proliferation in isolated female Han Wistar (HsdHanTM) rat hepatocyte cultures. Primary monolayer cultures of hepatocytes were prepared in 25 cm^2 flasks, 96- and 6-well plastic tissue culture plates in Leibowitz CL15 medium. Hepatocytes were cultured in Leibowitz CL15 medium for 4 h before the medium was removed and replaced with medium containing either the test material (1, 3, 10, 30, 65 and 100 µM), Phenobarbital sodium salt (positive control) or vehicle alone (negative control, 0.5% v/v dimethyl sulfoxide). After 96 h in culture, hepatocytes were either fixed using methanol at -20 °C (for assessment of replicative DNA synthesis) or harvested (for assessment of PROD and BROD activities) by scraping them into SET buffer, sonicating the mixture and storing it at –70 °C until analysis. Protein in hepatocytes scraped into SET buffer was determined.
- GLP compliance:
- no
- Type of method:
- in vitro
- Endpoint addressed:
- carcinogenicity
Test material
- Reference substance name:
- 632-619-2
- EC Number:
- 632-619-2
- Cas Number:
- 881685-58-1
- Molecular formula:
- C20 H23 F2 N3 O
- IUPAC Name:
- 632-619-2
Constituent 1
Administration / exposure
Doses / concentrationsopen allclose all
- Dose / conc.:
- 1 other: µM
- Dose / conc.:
- 3 other: µM
- Dose / conc.:
- 10 other: µM
- Dose / conc.:
- 30 other: µM
- Dose / conc.:
- 65 other: µM
- Dose / conc.:
- 100 other: µM
Results and discussion
- Details on results:
- The positive control compound phenobarbital sodium salt (PB) induced the expected effects (increased cell proliferation and induction of CYP2B) in cultured female rat hepatocytes, indicating that the experimental system responded as expected. The test substance induced similar effects, with increased cell proliferation and induction of CYP2B.
Any other information on results incl. tables
Adenosine 5’-triphosphate (ATP)
Treatment with 65 and 100 μM of the test material resulted in significant cytotoxicity, with intracellular ATP levels being reduced to 2 and 0.5 % of control, respectively. No concentration of PB tested induced toxicity.
Pentoxyresorufin-O-depentylation (PROD)
Treatment with 10 and 30 μM of the test material resulted in statistically significant increases in PROD activity to 6.6- and 4.1-fold control, respectively. Treatment with 100 and 1000 μM PB resulted in statistically significant increases in PROD activity to 4.0- and 5.8-fold control, respectively.
Benzyloxyresorufin-O-debenzylation (BROD)
Treatment with 3, 10 and 30 μM of the test material resulted in statistically significant increases in BROD activity to 1.4-, 2.2- and 2.7-fold control, respectively. Treatment with 100 and 1000 μM PB resulted in statistically significant increases in BROD activity to 2- and 2.6-fold control, respectively.
Replicative DNA synthesis (S-phase)
Treatment with 25 ng/mL EGF resulted in a statistically significant increase in replicative DNA synthesis to 4.4-fold control, indicating that the hepatocytes could proliferate following exposure to proliferative stimuli and therefore demonstrating their suitability for use in investigations involving assessing induction of proliferation. Treatment with the test material resulted in statistically significant increases in replicative DNA synthesis at all concentrations tested, to a maximum of 2.6-fold control at 3 μM. Treatment with PB resulted in concentration-dependent increases in replicative DNA synthesis, to a maximum of 2.4-fold control at 1000 μM.
Table 1. Biochemical parameters in cultured female rat hepatocytes.
Treatment |
ATP luminescence units releaseda |
S-phase labelling index (%)b |
PROD pmol resorufin/min/mgc |
BROD pmol resorufin/min/mgc |
Vehicle control (0.5% v/v DMSO) |
98723±3184 (100.0±3.2) |
5.01±0.56 (100.0±11.1) |
0.062±0.095 (100.0±153.8) |
1.22±0.17 (100.0±13.6) |
PB 10 µM |
100406±1704 (101.7±1.7) |
8.26±0.97** (164.9±19.3) |
0.068±0.028 (109.8±45.8) |
1.34±0.24 (110.4±19.4) |
PB 100 µM |
103556±4897 (104.9±5.0) |
10.82±0.80** (215.9±16.1) |
0.244±0.046* (395.5±73.7) |
2.47±0.20** (202.8±16.2) |
PB 1000 µM |
111624±3676** (113.1±3.7) |
12.16±0.36** (242.7±7.2) |
0.361±0.042** (584.3±67.5) |
3.18±0.60** (261.6±49.3) |
Test Material 1 µM |
104243±2998* (105.6±3.0) |
9.63±0.59** (192.2±11.7) |
0.091±0.060 (147.0±96.9) |
1.64±0.82 (135.2±67.8) |
Test Material 3 µM |
105273±4010* (106.6±4.1) |
12.90±1.04** (257.4±20.8) |
0.179±0.060 (289.6±97.1) |
1.66±0.17* (136.9±14.0) |
Test Material 10 µM |
104996±3428** (106.4±3.5) |
11.34±1.12** (226.4±22.4) |
0.410±0.118* (664.3±190.8) |
2.69±0.35** (221.4±28.6) |
Test Material 30 µM |
95483±4674 (96.7±4.7) |
10.94±2.19** (218.4±43.7) |
0.252±0.012* (408.0±19.8) |
3.33±0.69** (274.2±56.9) |
Test Material 65 µM |
1957±118** (2.0±0.1) |
9.74±1.32d (194.5±26.3) |
0.177±0.046d (286.0±74.7) |
1.36±0.20d (111.8±16.4) |
Test Material 100 µM |
464±46** (0.5±0.1) |
|
|
|
EGF 25 ng/mL |
|
22.11±1.79** (441.4±35.6) |
|
|
Values are mean ±SD, values in parenthesis are mean % control ±SD.
an = 6 per group,bn = 5 per group,cn = 3 per group.
*Statistically different from control (Student’s t-test (2-sided) p<0.05; ** p<0.01).
dNo statistical analyses performed due to excessive cytotoxicity.
Applicant's summary and conclusion
- Conclusions:
- The test material increased cell proliferation and induction of CYP2B, which was similar to the effects of the positive control compound phenobarbital sodium salt (PB).
- Executive summary:
This study investigated the ability of the test material to induce cytochrome P450 (CYP) 2B (CYP2B) activity, CYP3A activity and cell proliferation (measured as the change in replicative DNA synthesis (S-phase of the cell cycle)) in isolated female Han Wistar rat hepatocyte cultures. Phenobarbital sodium salt (PB) was included as a positive control. Primary monolayer cultures of hepatocytes were prepared in 25 cm^2 flasks, 96- and 6-well plastic tissue culture plates in Leibowitz CL15 medium. Hepatocytes were exposed to the test material at 6 concentrations (1, 3, 10, 30, 65 and 100 µM), PB at 3 concentrations (10, 100 and 1000 μM) or vehicle (0.5 % v/v dimethyl sulfoxide (DMSO)) alone for 96 h. There were 3 replicates for each concentration in 25 cm^2 flasks for CYP activity measurements (measured as pentoxyresorufin-O-depentylation (PROD) and benzyloxyresorufin-O-debenzylation (BROD) for CYP2B and CYP2B/3A, respectively), 5 replicates for each concentration in 6-well plates for replicative DNA synthesis (proliferation) analysis and 6 replicates for each concentration in 96-well plates for cell toxicity measurements (measured as the change in cellular adenosine-5’-triphosphate (ATP)).
Treatment with 65 and 100 μM of the test material resulted in significant cytotoxicity, with intracellular ATP levels being reduced to 2 and 0.5 % of control, respectively. As a result, CYP activity and replicative DNA synthesis measurements made following treatment with these concentrations were excluded from data analysis. No concentration of PB tested induced toxicity. Treatment with 10 and 30 μM of the test material resulted in statistically significant increases in PROD activity to 6.6- and 4.1-fold control, respectively. Treatment with 100 and 1000 μM PB resulted in statistically significant increases in PROD activity to 4.0- and 5.8-fold control, respectively. Treatment with 3, 10 and 30 μM of the test material resulted in statistically significant increases in BROD activity to 1.4-, 2.2- and 2.7-fold control, respectively. Treatment with 100 and 1000 μM PB resulted in statistically significant increases in BROD activity to 2- and 2.6-fold control, respectively. Treatment with the test material resulted in statistically significant increases in replicative DNA synthesis at all concentrations tested, to a maximum of 2.6-fold control at 3 μM. Treatment with PB resulted in concentration-dependent increases in replicative DNA synthesis, to a maximum of 2.4-fold control at 1000 μM.
The test material increased cell proliferation and induction of CYP2B, which was similar to the effects of the positive control compound phenobarbital sodium salt (PB).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.